JP2009537538A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009537538A5 JP2009537538A5 JP2009511049A JP2009511049A JP2009537538A5 JP 2009537538 A5 JP2009537538 A5 JP 2009537538A5 JP 2009511049 A JP2009511049 A JP 2009511049A JP 2009511049 A JP2009511049 A JP 2009511049A JP 2009537538 A5 JP2009537538 A5 JP 2009537538A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pimavanserin
- pharmaceutically acceptable
- composition according
- microcrystalline cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- RGSULKHNAKTFIZ-CEAXSRTFSA-N pimavanserin tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(OCC(C)C)=CC=C1CNC(=O)N(C1CCN(C)CC1)CC1=CC=C(F)C=C1.C1=CC(OCC(C)C)=CC=C1CNC(=O)N(C1CCN(C)CC1)CC1=CC=C(F)C=C1 RGSULKHNAKTFIZ-CEAXSRTFSA-N 0.000 claims 7
- 229940081770 pimavanserin tartrate Drugs 0.000 claims 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 6
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical group OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims 3
- 235000019359 magnesium stearate Nutrition 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 229960003300 pimavanserin Drugs 0.000 claims 3
- RKEWSXXUOLRFBX-UHFFFAOYSA-N pimavanserin Chemical compound C1=CC(OCC(C)C)=CC=C1CNC(=O)N(C1CCN(C)CC1)CC1=CC=C(F)C=C1 RKEWSXXUOLRFBX-UHFFFAOYSA-N 0.000 claims 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- 229920000881 Modified starch Polymers 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000010276 construction Methods 0.000 claims 2
- 239000007888 film coating Substances 0.000 claims 2
- 238000009501 film coating Methods 0.000 claims 2
- 239000012535 impurity Substances 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 230000000873 masking effect Effects 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80086406P | 2006-05-15 | 2006-05-15 | |
| US85466506P | 2006-10-26 | 2006-10-26 | |
| PCT/US2007/011720 WO2007133802A2 (en) | 2006-05-15 | 2007-05-15 | Pharmaceutical formulations of pimavanserin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009537538A JP2009537538A (ja) | 2009-10-29 |
| JP2009537538A5 true JP2009537538A5 (enExample) | 2010-07-01 |
Family
ID=38669082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009511049A Pending JP2009537538A (ja) | 2006-05-15 | 2007-05-15 | ピマバンセリン医薬製剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20070264330A1 (enExample) |
| EP (1) | EP2037918A2 (enExample) |
| JP (1) | JP2009537538A (enExample) |
| CA (1) | CA2652300A1 (enExample) |
| WO (1) | WO2007133802A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7790899B2 (en) * | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
| ES2423485T3 (es) * | 2007-03-19 | 2013-09-20 | Acadia Pharmaceuticals Inc. | Asociaciones de agonistas y antagonistas inversos 5-HT2A con antipsicóticos |
| WO2008144665A1 (en) * | 2007-05-18 | 2008-11-27 | Acadia Pharmaceuticals Inc. | Use of pimavanserin in the treatment of parkinson and symptoms thereof |
| WO2012060847A1 (en) * | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| CN102600146B (zh) * | 2012-04-11 | 2014-10-08 | 兆科药业（合肥）有限公司 | 一种盐酸乐卡地平和氯沙坦钾复方制剂及其制备方法 |
| WO2014075692A1 (en) * | 2012-11-19 | 2014-05-22 | Azanta A/S | Dispersible tablet |
| WO2014085362A1 (en) * | 2012-11-27 | 2014-06-05 | Acadia Pharmaceuticals Inc. | Methods for the treatment of parkinson's disease psychosis using pimavanserin |
| EP3325444B1 (en) | 2015-07-20 | 2021-07-07 | Acadia Pharmaceuticals Inc. | Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c |
| CN105929030B (zh) * | 2015-12-18 | 2018-08-21 | 重庆两江药物研发中心有限公司 | 一种哌马色林中有机杂质的检测方法 |
| US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
| WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
| WO2017172757A1 (en) * | 2016-03-29 | 2017-10-05 | Acadia Pharmaceuticals Inc. | 5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques |
| EP3558311A1 (en) | 2016-12-20 | 2019-10-30 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis |
| US11135211B2 (en) | 2017-04-28 | 2021-10-05 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
| WO2019046167A1 (en) | 2017-08-30 | 2019-03-07 | Acadia Pharmaceuticals Inc. | PIMAVANSERIN FORMULATIONS |
| WO2019113084A1 (en) | 2017-12-05 | 2019-06-13 | Sunovion Pharmaceuticals Inc. | Crystal forms and production methods thereof |
| CN118593482A (zh) | 2017-12-05 | 2024-09-06 | 赛诺维信制药公司 | 非外消旋混合物及其用途 |
| CN109908097A (zh) * | 2017-12-13 | 2019-06-21 | 北京万全德众医药生物技术有限公司 | 匹莫范色林口崩缓释片 |
| IT201800003736A1 (it) | 2018-03-19 | 2019-09-19 | Lundbeck Pharmaceuticals Italy S P A | Processo per la produzione di Pimavanserin |
| IT201800009690A1 (it) | 2018-10-23 | 2020-04-23 | Lundbeck Pharmaceuticals Italy Spa | Processo per la produzione di pimavanserina |
| WO2020092618A1 (en) | 2018-10-30 | 2020-05-07 | Acadia Pharmaceuticals Inc. | Methods of treating depression, anxiety and sexual dysfunction using the compound primavanserin |
| CN109613163B (zh) * | 2019-01-08 | 2021-01-26 | 丽珠集团新北江制药股份有限公司 | 一种酒石酸匹莫范色林及其杂质的检测方法 |
| CN109613164B (zh) * | 2019-01-08 | 2021-02-09 | 丽珠集团新北江制药股份有限公司 | 一种酒石酸匹莫范色林的检测方法 |
| MX2021014774A (es) | 2019-06-04 | 2022-02-03 | Sunovion Pharmaceuticals Inc | Formulaciones de liberacion modificada y usos de las mismas. |
| WO2021016369A1 (en) | 2019-07-22 | 2021-01-28 | Acadia Pharmaceuticals Inc. | Pimavanserin for trating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder |
| WO2021030607A1 (en) | 2019-08-15 | 2021-02-18 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating neurodegenerative diseases |
| US20230024202A1 (en) * | 2019-12-05 | 2023-01-26 | Fresenius Kabi Usa, Llc | Method for analyzing degarelix and associated products |
| US11648242B2 (en) * | 2019-12-12 | 2023-05-16 | Aurobindo Pharma Ltd | Pharmaceutical composition comprising pimavanserin, process of preparation and use thereof |
| WO2022094230A1 (en) | 2020-11-02 | 2022-05-05 | Acadia Pharmaceuticals Inc. | Compounds for treating psychosis or depression |
| WO2023128900A1 (en) * | 2021-12-30 | 2023-07-06 | Pharmactive Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical compositions comprising pimavanserin as active ingredient and relevant excipients |
| CN117074579B (zh) * | 2023-10-16 | 2023-12-22 | 江苏东科康德药业有限公司 | 一种氨磺必利口服溶液有关物质的分析方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8628475D0 (en) * | 1986-11-28 | 1987-01-07 | Glaxo Group Ltd | Medicaments |
| US6419956B1 (en) * | 1999-12-30 | 2002-07-16 | Ancile Pharmaceuticals | Odor-masking coating for a pharmaceutical preparation |
| CA2512639C (en) * | 2003-01-16 | 2012-10-30 | Acadia Pharmaceuticals Inc. | Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases |
| US20050065183A1 (en) * | 2003-07-31 | 2005-03-24 | Indranil Nandi | Fexofenadine composition and process for preparing |
| CA2550735A1 (en) * | 2003-12-22 | 2005-07-14 | Acadia Pharmaceuticals Inc. | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| PT1729739T (pt) * | 2004-03-29 | 2016-12-01 | Servier Lab | Processo para a preparação de uma composição farmacêutica sólida |
| CA2563743A1 (en) * | 2004-04-22 | 2005-11-03 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for the treatment of sexual disorders ii |
| US20050261278A1 (en) * | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
| US7820695B2 (en) * | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
| KR101260036B1 (ko) * | 2004-09-27 | 2013-05-06 | 아카디아 파마슈티칼스 인코포레이티드 | Ｎ－(４－플루오로벤질)－ｎ－(１－메틸피페리딘－４－일)－ｎ＇－(４－(２－메틸프로필옥시)페닐메틸)카르바미드와그의 타르트레이트염 및 결정형의 합성 |
| EA012220B1 (ru) * | 2004-10-19 | 2009-08-28 | Крка, Товарна Здравил, Д. Д., Ново Место | Твёрдая фармацевтическая композиция, содержащая донепезила гидрохлорид |
-
2007
- 2007-05-15 JP JP2009511049A patent/JP2009537538A/ja active Pending
- 2007-05-15 EP EP07794929A patent/EP2037918A2/en not_active Withdrawn
- 2007-05-15 US US11/749,110 patent/US20070264330A1/en not_active Abandoned
- 2007-05-15 CA CA002652300A patent/CA2652300A1/en not_active Abandoned
- 2007-05-15 WO PCT/US2007/011720 patent/WO2007133802A2/en not_active Ceased